Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. It increases body’s immune power... It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.
- Mechanism
- Curator reviewed
Oral talactoferrin stimulated the production of the immunostimulatory cytokine IL-18 in mice, increasing IL-18 levels both in the gut and in systemic circulation. Oral talactoferrin was also shown to stimulate the activity of NK cells and to increase the production and activity of key circulating immune cells.
- Primary indication
- Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers.Curator reviewed
- Code names
- LF-00
Resolves to
What you can answer from here — as of April 23, 2025
Which companies are running trials of Talactoferrin alfa, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account